Initial Experience with Commercial Transcatheter Mitral Valve Repair in the United States

Paul Sorajja*, Michael MacK, Sreekanth Vemulapalli, David R. Holmes, Amanda Stebbins, Saibal Kar, D. Scott Lim, Vinod Thourani, Patrick McCarthy, Samir Kapadia, Paul Grayburn, Wesley A. Pedersen, Gorav Ailawadi

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

153 Scopus citations


Background Transcatheter mitral valve (MV) repair with the MitraClip received approval in 2013 for the treatment of prohibitive-risk patients with primary mitral regurgitation (MR). Objectives The aim of this study was to report the initial U.S. commercial experience with transcatheter MV repair. Methods Data from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry on patients commercially treated with this percutaneous mitral valve repair device were analyzed. Results Of 564 patients (56% men, median age 83 years), severe symptoms were present in 473 (86.0%). The median Society of Thoracic Surgeons Predicted Risk of Mortality scores for MV repair and replacement were 7.9% (interquartile range: 4.7% to 12.2%) and 10.0% (interquartile range: 6.3% to 14.5%), respectively. Frailty was noted in 323 patients (57.3%). Transcatheter MV repair was performed for degenerative disease, present in 90.8% of patients. Overall, MR was reduced to grade ≤2 in 93.0%. In-hospital mortality was 2.3%; 30-day mortality was 5.8%. Other 30-day events were stroke (1.8%), bleeding (2.6%), and device-related complications (1.4%). The median length of stay was 3 days (interquartile range: 1 to 6 days), with 84.0% patients discharged home. Overall, procedure success occurred in 90.6%. Variables associated with reduction in MR were end-diastolic dimension, MR severity, clip location, and case volume. Conclusions In this study of the initial commercial U.S. experience, it was found that procedural success was achieved in approximately 91% of patients, and the majority of patients were discharged home with moderate or less MR. These data support the effectiveness of this therapy in appropriately selected high-risk patients in a commercial setting. Further study is required to determine the long-term impact of transcatheter MV repair in this patient population.

Original languageEnglish (US)
Pages (from-to)1129-1140
Number of pages12
JournalJournal of the American College of Cardiology
Issue number10
StatePublished - Mar 15 2016


  • Key Words mitral regurgitation
  • mitral repair
  • transcatheter

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Initial Experience with Commercial Transcatheter Mitral Valve Repair in the United States'. Together they form a unique fingerprint.

Cite this